GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited
Aktie · INE159A01016 (XNSE)
Übersicht
Kein Kurs
Schlusskurs XNSE 04.11.2025: 2.658,50 INR
04.11.2025 10:00
Aktuelle Kurse von GlaxoSmithKline Pharmaceuticals Limited
BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNSE: NSE
NSE
GLAXO.NS
INR
04.11.2025 10:00
2.658,50 INR
-24,30 INR
-0,91 %
XBOM: MSE
MSE
GLAXO.BO
INR
04.11.2025 09:59
2.661,50 INR
-21,30 INR
-0,79 %
Free Float & Liquidität
Free Float 24,35 %
Shares Float 41,25 M
Ausstehende Aktien 169,4 M
Firmenprofil zu GlaxoSmithKline Pharmaceuticals Limited Aktie
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of Shingles and Post herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; TENOVATE and Flutivate for skin conditions to reduce inflammation; PHYSIOGEL for dry skin and dry skin associated with redness and itch; Zimig for fungal skin infections; COBADEX CZS, a multivitamin; and Supacef, a bactericidal cephalosporin antibiotic. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
Erhalte tagesaktuelle Insights vom finAgent über GlaxoSmithKline Pharmaceuticals Limited

Unternehmensdaten

Name GlaxoSmithKline Pharmaceuticals Limited
Firma GlaxoSmithKline Pharmaceuticals Limited
Website https://india-pharma.gsk.com
Heimatbörse XNSE NSE
ISIN INE159A01016
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - General
CEO Bhushan Akshikar
Marktkapitalisierung 453 Mrd.
Land Indien
Währung INR
Mitarbeiter 3,2 T
Adresse GSK House, 400030 Mumbai
IPO Datum 2000-01-03

Ticker Symbole

Name Symbol
MSE GLAXO.BO
NSE GLAXO.NS
Weitere Aktien
Investoren, die GlaxoSmithKline Pharmaceuticals Limited halten, haben auch folgende Aktien im Depot:
Gulf Energy Development Public Company Limited
Gulf Energy Development Public Company Limited Aktie
SILVER BULLET MINES CORP.
SILVER BULLET MINES CORP. Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025